Human Development Research Centre, SICS, A*STAR
Singapore, 117597
NCT Number: NCT06119035
The study aims to evaluate insulin as a potential biomarker for prediabetes in Singapore Chinese subjects.
Looking for future studies?
Notify Me21 year–60 year
All sexes
Interventional
Not applicable
Singapore, 117597
The prevalence of type 2 diabetes (T2DM) in Singapore is expected to increase from 400,000 to 1,000,000 individuals by 2050, resulting in nearly US$2 billion in economic costs. Pre-diabetes is defined as an intermediate state of hyperglycemia where blood glucose levels are elevated but are below the diagnostic levels of diabetes. In Singapore, approximately 1 in 7, or 430,000 residents are estimated to be pre-diabetic, and globally this number is estimated at 7.3% of adults (equivalent to 352.1 million individuals). Up to 70% of pre-diabetics eventually develop overt T2DM; however, pre-diabetes may be reversible with early detection, providing a window for opportune disease interception.
While blood glucose is currently used to detect pre-diabetes, homeostatic mechanisms can maintain normal blood glucose levels and mask the detection of pre-diabetes until overt hyperglycemia is exhibited. In contrast, numerous studies have demonstrated that insulin levels increase markedly in pre-diabetes, even as marginal changes are observed in glucose levels. In this study, the investigator aims to determine if dynamic insulin levels observed during an oral glucose tolerance test are more sensitive than glucose alone in detecting prediabetes in a Singapore Chinese population.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Consume single dose of 75 grams glucose in 200ml water
Time frame: 0 minutes
Blood samples will be collected at 1 time point before intervention administration
Time frame: 4 hours 30 minutes
Blood samples will be collected at 17 time points
Time frame: 4 hours 30 minutes
Blood samples will be collected at 17 time points
Time frame: up to 3 years
Serum samples will be frozen for additional future analysis
Singapore Institute of Food and Biotechnology Innovation
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07618663
Diabetes Mellitus, Endocrine System Diseases
Lahore, Shaikhupura, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial DetailsNCT07713394
Behavior, Body Weight
Erzurum, Turkey, Turkey (Türkiye)
View Trial DetailsNCT07710898
Diabete Mellitus, Diabetes Mellitus
Lahore, Pakistan
View Trial Details